Novel Agent Works in Primary Progressive MS (CME/CE)

(MedPage Today) -- Ocrelizumab cuts progression risk by 24%, study finds
Source: MedPage Today Meeting Coverage - Category: Journals (General) Source Type: news
More News: General Medicine | Study